Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The global pharmaceutical excipients market is projected to witness a CAGR of 7.31% during the forecast period to reach a total market size of $9.776B by 2026, increasing from $5.966B in 2019.
read more
Bausch Health Companies and its gastroenterology business Salix Pharmaceuticals, today responded to the U.S. Food and Drug Administration's (FDA) tentative approval of the Norwich Pharmaceuticals rifaximin 200 mg product.
read more
Positive long-term follow-up results from the PAOLA-1 and SOLO-1 Phase III trials of LYNPARZA® (olaparib), jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, with or without bevacizumab demonstrated clinically meaningful improvements in overall survival (OS).
read more
The global nutritional supplements market size is expected to reach $620.8B by 2030, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 6.3% from 2022 to 2030.
read more
The global digestive health market is expected to hit $83.69B by 2030 and to grow at a CAGR of 7.9% during the forecast period, according to Growth Plus Reports. A rise in awareness for gut health and adoption of probiotics is a major driver, according to the report
read more
The antifungal drugs market size was valued at 16.6B in 2020, and is estimated to reach $25.0B by 2030, growing at a CAGR of 3.9% from 2021 to 2030.
read more
The global bone and joint supplement market was valued at $10.8B in 2021 and is expected to grow by 8.2% by the end of 2030, according to a study published by Growth Market Reports. The global bone & joint health supplements market growth is attributed to the increasing geriatric population and rising incidence of bone and joint diseases among them...
read more
The Syntegon Group, a supplier of processing and packaging technology, will appoint Dr. Peter Hackel as member of the Executive Board at the beginning of 2023.
read more
The quinidine sulfate market size is expected to grow by $427.29M from 2021 to 2026. In addition, the growth momentum of the market will accelerate at a CAGR of 6.7% during the forecast period, according to a study by Technavio.
read more
Singapore-headquartered Everstone Capital, private equity arm of the Everstone Group, announced the acquisition of a controlling stake in Softgel Healthcare, a specialized niche dosage form focused manufacturing player catering to the global nutraceutical, pharmaceutical and OTC segments.
read more
The global pharmaceutical excipients market is projected to witness a CAGR of 7.31% during the forecast period to reach a total market size of $9.776B by 2026, increasing from $5.966B in 2019.
read more
Aurinia Pharmaceuticals, a biopharmaceutical company specializing in autoimmune diseases, announced that the European Commission (EC) has granted marketing authorization of LUPKYNIS® (voclosporin) to treat adults with active lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE).
read more
The market for Dietary Supplements is estimated at $155.2B in 2022; it is projected to grow at a CAGR of 7.3% to reach $220.8B by 2027, according to a Research & Markets report.
read more
Experic, a contract development and manufacturing organization (CDMO) and clinical supply services company serving the pharmaceutical industry, announced the appointment of Derek Hennecke as an independent member of its board of directors.
read more
Roquette, a provider of pharmaceutical and nutraceutical excipients, announces its complete acquisition of India-based excipient manufacturer, Crest Cellulose.
read more